Latest Mena Region News

Unith Ltd boosted its AI digital human platform with ISO/IEC 27001:2022 certification, launched new SDKs, and secured $2.75 million in fresh capital to fuel growth and commercial expansion.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Recce Pharmaceuticals secured A$4 million through an institutional placement and launched a Share Purchase Plan to raise up to an additional A$4 million, bolstering funds for commercial licensing and ongoing clinical programs.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.

Parkway Corporate has teamed up with Hitachi to develop modular ultra-high brine concentration systems, crucial for its flagship Queensland Brine Management Complex project aimed at transforming industrial waste brine into green chemicals.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

Frontier Digital Ventures reported an 18% decline in statutory revenue to A$54.8 million for 2025, while operating EBITDA surged 205% to A$9.1 million, despite a net loss of A$18 million impacted by a significant goodwill impairment and a fraud incident in Colombia.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.